GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, Inc., Boehringer Ingelheim
The latest healthcare forecast report provides an in-depth analysis of CTD-ILD, offering comprehensive insights into the CTD-ILD revenue trends, prevalence, and treatment landscape. The report delves into key CTD-ILD statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging CTD-ILD therapies. Additionally, we cover the landscape of CTD-ILD clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of CTD-ILD treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the CTD-ILD space.
The CTD-ILD market size was valued ~USD 1,498 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In 2023, the United States held the largest market share for Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), contributing approximately 70% of the total market size across the 7MM. This was significantly higher compared to other key markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
In 2023, Germany recorded the largest market size for Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) among EU countries, reaching nearly USD 84 million, while Spain had the smallest market size at USD 38 million.
Japan's market size for Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) was approximately USD 136 million in 2023, representing 9% of the total market across the 7MM.
Key CTD-ILD Companies: GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, Inc., Boehringer Ingelheim Pharmaceuticals, and others
Key CTD-ILD Therapies: Belimumab, bosentan, Tulisokibart, Rituximab, Vixarelimab, OFEV, Belimumab, GSK1550188 (BENLYSTA), and others
The CTD-ILD market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage CTD-ILD pipeline products will significantly revolutionize the CTD-ILD market dynamics.
According to DelveInsight's evaluation, the total prevalent cases of Interstitial Lung Disease (ILD) in the 7MM were approximately 1,662,000 in 2023.
In 2023, the United States recorded the highest number of diagnosed prevalent cases of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), approximately 132,000, with numbers anticipated to increase in the future.
Within Europe, the UK reported the highest number of diagnosed prevalent cases of CTD-ILD in 2023, approximately 27,000, followed by Germany with 25,000 cases. In contrast, Spain had the lowest prevalence, with around 11,000 cases.
In 2023, Japan reported approximately 68,000 diagnosed prevalent cases of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), representing around 23% of the total cases across the 7MM.
In the US in 2023, type-specific diagnosed cases of CTD-ILD were highest for pSS-ILD (approximately 38,000), followed by SSc-ILD (around 31,000), Other CTD-ILDs (roughly 30,000), RA-ILD (about 20,000), DM-ILD/PM-ILD (close to 8,000), and SLE-ILD (nearly 5,000).
Connective Tissue Disease associated with Interstitial Lung Disease Overview
Connective Tissue Disease (CTD)-associated Interstitial Lung Disease (ILD) refers to a group of lung disorders that occur as a result of underlying connective tissue diseases. These diseases, such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, and polymyositis, can cause inflammation and scarring in the lungs, leading to ILD. This condition results in impaired lung function, breathing difficulties, and decreased oxygen levels. The damage is often progressive and can lead to respiratory failure if left untreated. Early diagnosis and management are crucial to managing symptoms and slowing disease progression. Treatment typically involves immunosuppressive medications and management of the underlying CTD.
CTD-ILD Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Connective Tissue Disease associated with Interstitial Lung Disease Epidemiology Segmentation:
The CTD-ILD market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Download the report to understand which factors are driving CTD-ILD epidemiology trends @ CTD-ILD Epidemiology Forecast
CTD-ILD Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the CTD-ILD market or expected to get launched during the study period. The analysis covers CTD-ILD market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the CTD-ILD Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
CTD-ILD Therapies and Key Companies
Belimumab: GlaxoSmithKline
bosentan: Actelion
Tulisokibart: Prometheus Biosciences
Rituximab: Eric Matteson
Vixarelimab: Genentech, Inc.
OFEV: Boehringer Ingelheim Pharmaceuticals, Inc.
Belimumab, GSK1550188 (BENLYSTA): GlaxoSmithKline plc.
Connective Tissue Disease associated with Interstitial Lung Disease Market Drivers
Increasing Prevalence of CTD-ILD
Advances in Diagnostic Techniques
Emergence of Novel Therapies
Rising Awareness Among Healthcare Providers
Aging Population
Regulatory Approvals for Targeted Treatments
Supportive Healthcare Policies
Connective Tissue Disease associated with Interstitial Lung Disease Market Barriers
High Cost of Treatment
Limited Drug Approvals
Challenges in Early Diagnosis
Heterogeneity of CTD-ILD
Side Effects of Current Treatments
Lack of Awareness in Emerging Markets
Inconsistent Clinical Guidelines
Scope of the Connective Tissue Disease associated with Interstitial Lung Disease Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key CTD-ILD Companies: GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, Inc., Boehringer Ingelheim Pharmaceuticals, and others
Key CTD-ILD Therapies: Belimumab, bosentan, Tulisokibart, Rituximab, Vixarelimab, OFEV, Belimumab, GSK1550188 (BENLYSTA), and others
CTD-ILD Therapeutic Assessment: CTD-ILD current marketed and CTD-ILD emerging therapies
CTD-ILD Market Dynamics: CTD-ILD market drivers and CTD-ILD market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Table of Contents
1. CTD-ILD Market Report Introduction
2. Executive Summary for CTD-ILD
3. SWOT analysis of CTD-ILD
4. CTD-ILD Patient Share (%) Overview at a Glance
5. CTD-ILD Market Overview at a Glance
6. CTD-ILD Disease Background and Overview
7. CTD-ILD Epidemiology and Patient Population
8. Country-Specific Patient Population of CTD-ILD
9. CTD-ILD Current Treatment and Medical Practices
10. CTD-ILD Unmet Needs
11. CTD-ILD Emerging Therapies
12. CTD-ILD Market Outlook
13. Country-Wise CTD-ILD Market Analysis (2020–2034)
14. CTD-ILD Market Access and Reimbursement of Therapies
15. CTD-ILD Market Drivers
16. CTD-ILD Market Barriers
17. CTD-ILD Appendix
18. CTD-ILD Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
32 minutes ago
- Globe and Mail
USB vs. MTB: Which Regional Banking Stock Holds More Upside?
Both U.S. Bancorp USB and M&T Bank Corporation MTB are U.S. regional banks, offering similar banking services and exposed to the same interest-rate and credit-cycle pressures. Their performance often mirrors sector-wide trends in net interest margins, deposit competition, and loan defaults. However, both have different growth strategies and geographic exposures. Let us delve deeper into the financial outlook, valuation, and risk profiles of USB and MTB to determine which stock offers better value. The Case for USB U.S. Bancorp has been making several strategic initiatives to strengthen its market position, digital capabilities, and diversify revenue streams. In the past few years, USB has acquired Salucro Healthcare Solutions LLC, MUFG Union Bank's core franchise and fintech platforms. In June 2025, USB partnered with Fiserv to integrate its Elan Financial Service credit card program into Fiserv's Credit Choice Solution. These efforts will continue to strengthen the company's fee-based businesses. Over the past few years, the company has been witnessing a rise in net interest income (NII). Going forward, investment portfolio repositioning, less deposit migration, relatively lower rates, and stabilizing funding costs will continue to support its NII growth. Organic growth and diverse revenue sources are key strengths of U.S. Bancorp. Hence, the company is well-positioned to improve its revenue trend, backed by growth in non-interest income and NII. The company has been experiencing solid growth in average loans and deposits in recent years as it expands relationships with existing customers and acquires new ones. Also, stabilizing deposit trends will continue to support deposit growth. These favorable factors will continue to aid its top line. Management projects total revenues for 2025 to grow in the range of 3–5% from the $27.6 billion reported in 2024. USB Sales Estimates The company enjoys a decent balance sheet. As of March 31, 2025, the company had long-term debt of $59.9 billion and $17 billion in short-term borrowings. Cash and due from banks was $50 billion as of the same date, reflecting a decent liquidity position. Furthermore, USB has cleared the 2025 stress test result and announced plans to increase its quarterly dividend by 4% to 52 cents per share, subject to the board's approval. It also intends to continue buybacks under its existing $5 billion share repurchase program. As of March 31, 2025, $4.9 billion remains available under the company's repurchase program. Given its decent liquidity and strong capital position, its capital deployment activities are sustainable. The Case for MTB M&T Bank has shown remarkable revenue growth over the past few years. Going forward, higher NII, driven by modest lending demand and the Fed's rate cuts, will support its revenue growth. The company's initiatives to strengthen non-interest income will further bolster the top-line growth. The company has a solid balance sheet position. It has been focused on acquiring the best deposit franchise. The company recorded solid loan and deposit growth in the past few years. Growth was supported by the acquisition of People's United in 2022, which increased M&T Bank's loans by $36 billion and deposits by $53 billion. Its deposits are well diversified in terms of clients and offerings, which will support growth in the upcoming period. Additionally, improvements in consumer, commercial, and industrial (C&I) and residential mortgage lending will support loan growth. Management expects 2025 average loans and leases to be between $135 billion and $137 billion, while average total deposits are projected to be in the range of $162–$164 billion in 2025. Last year, total loans and leases amounted to $135.5 billion, while total deposits reached $161 billion. NII is also anticipated to be between $7.05 billion and $7.15 billion for 2025. Additionally, non-interest income is expected to be between $2.5 billion and $2.6 billion. Last year, NII was $6.85 and non-interest income was $$2.4 billion. These favorable projections will likely support the company's top line. MTB Sales Estimates The financial position of M&T Bank remains healthy, backed by strong liquidity and manageable debt levels. As of March 31, 2025, the company had total borrowings of $12.1 billion, comprising both short-term and long-term debt, which was lower than the $22.8 billion held in cash and interest-bearing deposits at banks as of the same date. The company has also passed this year's stress test, although it is yet to announce any changes to its capital plans. M&T Bank hiked its quarterly dividends by 4% to $1.35 per share in May 2024. This followed an 8.3% increase in February 2023. Further, in January 2025, its board of directors authorized a share repurchase program to repurchase up to $4 billion of the company's common stock, with no expiration date. As of March 31, 2025, $3.3 billion worth of shares were available under the plan. USB & MTB: Price Performance and Valuation Over the three months, shares of USB and MTB rallied 19.9% and 20.9% outperforming the industry 's growth of 18.8% and the S&P 500 Index's increase of 15.1%. Price Performance Image Source: Zacks Investment Research In terms of valuation, USB currently trades at a forward 12-month price-to-earnings (P/E) ratio of 10.33 times, which is lower than its five-year median of 10.75 times. MTB stock is currently trading at a 12-month forward P/E of 11.42X, which is higher than its five-year median of 10.56X. Price-to-Earnings F12M Further, USB is trading at a discount compared with the industry average of 11.13X, while MTB is trading at a premium. Hence, USB is a better choice for value investors. How Do Earnings Estimates Compare USB & MTB? The Zacks Consensus Estimate for USB's 2025 and 2026 earnings indicates an 8% and 9.6% rise for 2025 and 2026, respectively. Earnings estimates for 2025 have been revised downward, while the same have been revised upward for 2026 over the past month. USB Estimates Revision Trend Image Source: Zacks Investment Research The consensus mark for MTB's 2025 and 2026 earnings indicates an 8.5% and 14.7% rise for 2025 and 2026, respectively. Earnings estimates for both years have been revised upward over the past month. MTB Estimates Revision Trend Image Source: Zacks Investment Research USB or MTB: Which Bank Stock Is More Compelling? While both USB and MTB are fundamentally strong regional banks with robust balance sheets and consistent capital returns, USB stands out as the more compelling investment choice for value-oriented investors and those seeking long-term growth. USB is trading below both its five-year median and the industry average, which signals an attractive valuation entry point. Its strategic acquisitions, fintech partnerships, and diversified revenue mix position it well capitalized on for long-term growth. Moreover, its strong capital position, planned dividend increase, and active buyback plan underscore management's confidence in delivering sustainable shareholder returns. While MTB offers appealing earnings momentum, USB's lower valuation, broader strategic initiatives, and balanced revenue sources give it the edge in terms of total return potential and long-term upside. At present, USB and MTB carry a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up U.S. Bancorp (USB): Free Stock Analysis Report M&T Bank Corporation (MTB): Free Stock Analysis Report
Winnipeg Free Press
2 hours ago
- Winnipeg Free Press
Court orders reinstatement of convictions of ex-Fox executive, marketing firm in FIFA bribery case
NEW YORK (AP) — A federal appeals court on Tuesday ordered reinstatement of the convictions of a former Fox executive and a South American sports media and marketing company in the FIFA bribery investigation. Hernan Lopez, the former CEO of Fox International Channels, was convicted by a jury in March 2023 along with the marketing company Full Play Group SA of one count each of wire fraud conspiracy and money laundering conspiracy related to the Copa Libertadores soccer tournament. Full Play was convicted of two additional counts each of wire fraud conspiracy and money laundering conspiracy related to World Cup qualifiers and friendlies and to the Copa America, the continent's national team championship. U.S. District Judge Pamela K. Chen, who presided over the trial in Brooklyn federal court, granted a motion for an acquittal in September 2023, citing a May 2023 decision by the U.S. Supreme Court in cases involving Joseph Percoco, an aide to former New York Gov. Andrew Cuomo, and construction firm owner Louis Ciminelli. Chen wrote those decisions meant Lopez's conviction could not be sustained under the honest services fraud statute. The U.S. government then appealed. U.S. Senior Circuit Judge John M. Walker Jr. and U.S. Circuit Judges Beth Robinson and Sarah A. L. Merriam vacated Chen's decision and ordered her to reinstate the convictions and to conduct additional proceedings consistent with their opinion. Walker, writing for the panel, said 'the nature of defendants' conduct (bribery), coupled with the character of the relationship between the bribed officials and the organizations to whom they owed a duty of loyalty (employer-employee relationships), place the schemes presumptively within the scope of' the statute. They added: 'The foreign identity of certain organizations and officials does not remove the schemes from the ambit of' the statute, 'especially where, as here, relevant conduct occurred in the United States, for the benefit of United States-based executives and organizations (e.g., Lopez and Fox), and the victims were multinational organizations with global operations and significant ties to the United States.' The circuit judges said it was up to Chen to decide whether to grant a defense motion questioning whether the government's evidence was sufficient to prove a conspiracy to deceive the South American governing body CONMEBOL. 'The proceedings that resulted in Hernan's conviction were afflicted with numerous defects,' John Gleeson, a lawyer for Lopez, wrote in an email to The Associated Press. 'Today, the Court of Appeals ruled against us on one discrete legal issue — the same issue that we believe Judge Pamela Chen ruled on correctly when she acquitted our client after trial. We intend to seek review of that issue in the Supreme Court of the United States, and have no doubt that our client will eventually be fully vindicated.' Mayling C. Blanco and Michael Martinez, lawyers for Full Play, did not respond to emails from the AP seeking comment. The U.S. Attorney's Office for the Eastern District of New York had no comment. Thursdays Keep up to date on sports with Mike McIntyre's weekly newsletter. Dozens of people have pleaded guilty or been convicted after a U.S.-led investigation into FIFA and international soccer. The probe became public in 2015 when U.S. prosecutors accused the leaders of soccer federations of tarnishing the sport for nearly a quarter-century by taking $150 million in bribes and payoffs. 'Corruption in international soccer is not new,' the circuit court wrote. 'It was rampant for decades before the events at issue here.' Fox Corp., which split from a subsidiary of international channels during a restructuring in 2019, was not charged and has denied any involvement in the bribery scandal. ___ AP soccer:
Globe and Mail
3 hours ago
- Globe and Mail
Saudi German Health UAE is Raising the Bar for Patient Experience
Dubai, United Arab Emirates--(Newsfile Corp. - July 2, 2025) - Saudi German Health UAE, one of the region's most prominent healthcare networks, has completed a critical milestone in its ongoing transformation to embed "hospitality-caliber" service into the heart of healthcare operations. In partnership with CXM, a strategic experience transformation partner, the hospital is reimagining what it means to "care like family"- not as a slogan, but as a lived, system-wide reality. To view an enhanced version of this graphic, please visit: From Vision to Execution: Embedding "Hospitality-Caliber" Care into the Hospitals Operating Model What began months ago as a vision to reimagine how patients are treated not just medically, but emotionally and operationally has evolved into a structured, hospital-wide program. Today, with Phase 2 finalized, Saudi German Health UAE continues this journey with renewed momentum and system-wide alignment. "Patient Experience is built when people don't just follow steps, they believe in the purpose behind them. At Saudi German Health UAE, we've been aligning care, culture, and operations around one shared truth: experience is not an initiative, it's how we lead, how we work, and how we serve." - Dr. Ahmed Eissa, Group CEO, Saudi German Health UAE Every touchpoint, team interaction, and daily routine is being re-examined through the lens of experience: how care is felt, not just how it is delivered. In collaboration with CXM, more than 850 team members stepped into a journey of reflection, co-creation, and cultural alignment. From leadership presence to frontline dialogue, the hospital activated new ways of working rooted in empathy, clarity, and shared purpose. Experience by Design: Realigning Hospital Teams Around Purpose and Patient Outcomes Now, as the transformation moves forward, Saudi German Health UAE is preparing to enter its next chapter: co-designing the behavioral and experiential elements that will bring the philosophy of Caring Like Family to life in even deeper, more human-centered ways. This will include reimagining onboarding, empowering peer-to-peer recognition, enhancing patient journey design, and creating signature moments that leave lasting emotional impact. "What Saudi German Health UAE has chosen isn't easy. But it's real. And it shows what's possible when patient experience is treated not as a layer but as the operating system." - Raluca Berchiu, Founder & CEO, CXM How Saudi German Health UAE is Setting a Benchmark in Patient Experience Saudi German Health UAE is among the first healthcare institutions in the UAE to treat "hospitality-caliber" service as essential infrastructure equal in importance to clinical protocols and operational workflows. This is about building emotional connection with patients, a level of personalization and attentiveness they expect from other industries but rarely experience in healthcare. CXM continues to support this evolution translating vision into operational reality, ensuring "hospitality-caliber" experience is not just felt, but sustained. For more information please visit About Saudi German Health UAE Saudi German Health UAE is one of the region's most prominent healthcare networks, dedicated to delivering world-class medical care with a human touch. Grounded in the philosophy of Caring Like Family, it continues to raise the bar for what excellence in healthcare truly feels like. About CXM CXM is a strategic transformation partner helping hospitals and healthcare systems lead in a patient-centred era. With a focus on growth, operational excellence, and experience innovation, CXM supports healthcare leaders in embedding lasting change across performance, culture, and care delivery. Through its Hospitality-Driven Patient Experience Model, CXM translates bold experience visions into operational reality guiding transformation from strategy to execution
